96036-03-2

• 常用中文名：美罗培南
• 常用英文名：Meropenem
• CAS号：96036-03-2
• 分子式：C₁₇H₂₅N₃O₅S
• 分子量：383.462
• 相关类别： 原料药 抗生素类药物 β-内酰胺酶抑制剂
• 发布时间：2018-07-22 11:27:37
• 更新时间：2026-06-29 16:12:06
• Meropenem是碳青霉烯类广谱抗菌素。

名称

• 中文名: 美罗培南
• 英文名: meropenem
• 中文别名: 美罗培南检测标准品; 美罗培南 / 美洛培南; 美罗培南/三水/粗品; (4R,5S,6S)-3-(((3S,5S)-5-(二甲基氨甲酰)吡咯烷-3-基)硫代)-6-((R)-1-羟乙基)-4-甲基-7-氧代-1-氮杂双环[3.2.0]庚-2-烯-2-羧酸; 麦洛派南; 美罗培南对照品; 美诺配南; 美洛培南(无水); 鸡内金; (-)-(4R,5S,6S)-3-[[(3S,5S)-5-(二甲基氨甲酰基)-3; 3-[[5-[(二甲氨基)羰基]-3-吡咯烷基]硫代]-6-(1-羟乙基)-4-甲基-7-氧代-1-氮杂双环[3,2,0]庚-2-烯-2-羧酸; (4R,5S,6S)-3-[[(3S,5S)-5-[(二甲基氨基)羰基]-3-吡咯烷基]硫基]-6-[(1R)-1-羟乙基]-4-甲基-7-氧代-1-氮杂二环[3.2.0]庚-2-烯-2-羧酸; 美罗陪南; 美罗培南Meropenem; 美罗陪南(碳酸钠)无菌粉; Meropenem 美罗培南(β-内酰胺抗生素); Meropenem 美罗培南（β-内酰胺抗生素）; (-)-(4R, 5S, 6S)-3-[[(3S, 5S)-5-(二甲基氨甲酰基)-3; 3-[[5-[(二甲氨基)羰基]-3-吡咯烷基]硫代]-6-(1-羟乙基)-4-甲基-7-氧代-1-氮杂双环[3,2,0]庚-2-烯-2-羧酸/美罗培南/美诺配南/麦洛派南/(-)-(4R, 5S, 6S)-3-[[(3S, 5S)-5-(二甲基氨甲酰基)/美罗陪南/美洛培南; 美洛培南; 美罗培南(无水); 美洛培南、美诺配南、麦洛派南; 碳青霉烯类抗生素; 美罗培南(含碳酸钠); (-)-(4R,5S,6S)-3-[[(3S,5S)-5-(二甲基氨甲酰基)
• 英文别名: (4R,5β)-3-[[(3S)-5β-[[(Dimethylamino)carbonyl]]pyrrolidin-3-yl]thio]-6β-[(R)-1-hydroxyethyl]-4α-methyl-7-oxo-1-azabicyclo[3.2.0]ht-2-ene-2-cboxylic acid; MEROPENEM, ANTIBIOTIC FOR CULTURE MEDIA USE ONLY; 4R,5S,6S)-3-[[(3S,5S)-5-[(Dimeth-ylamino)carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]ht-2-ene-2-cboxylic acid; (4R,5S,6S)-3-[[(3S,5S)-5-[(Dimethylamino)carbonyl]pyrrolidin-3-yl]thio]-6-[(R)-1-hydroxyethyl]-4α-methyl-7-oxo-1-azabicyclo[3.2.0]ht-2-ene-2-cboxylic acid; Merrem; MEROPENEM, STANDD; Meropenem, >=; Meronem; MEROPENEM FOR INJECTION; MEROPENEM, 1 G; Meropen; Meropenem //BP; SM 7338; (1'R,3'S,5'S,4R,5S,6S)-3-(5-DIMETHYLCARBAMOYL-PYRROLIDIN-3-YLSULFANYL)-6-(1-HYDROXY-ETHYL)-4-METHYL-7-OXO-1-AZA-BICYCLO[3.2.0]HEPT-2-ENE-2-CARBOXYLIC ACID; (4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; crude ade meropenem; antibioticsm7338; MEROPENEM(PATENTED); STERILE MIXTURE OF MEROPENEM AND SODIUM CBONATE; 5-beta,6-beta(r*)))-ph; (4r,5s,6s)-3-[[(3s,5s)-5-(dimethylcbamoyl)pyrrolidin-3-yl]thio]-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]ht-2-ene-2-cboxylic acid; MERONEM MEROPEN MEROPENEM MERREM; 1-Azabicyclo[3.2.0]ht-2-ene-2-cboxylic acid, 3-[[(3S,5S)-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, (4R,5S,6S)- (9CI); (4R,5S,6S)-3-[[(3S,5S)-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicycl 0[3.2.0]hept-2-ene-2-carboxylic acid; Meropenem Powder Standd; 1-Azabicyclo[3.2.0]ht-2-ene-2-cboxylic acid, 3-[[(3S,5S)-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, (4R,5S,6S); MeropeneM Crude; ici194660; MFCD00864966; Meropenem (Secondy Standd)Q: What is Meropenem (Secondy Standd) Q: What is the CAS Number of Meropenem (Secondy Standd); )-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-,(4r-(3(s*,5s*),4-al; Meropenemanhydrous; STERILE MEROPENEM; [4R-[3(3S*,5S*),4a,5b,6b(R*)]]-3-[[5-[(Dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic Acid; (1R,5S,6S)-2-[(3S,5S)-5-(Dimethylaminocarbonyl)pyrrolidin-3-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic Acid; MEROPENEM (PATENTED); (4R,5S,6S)-3-[[(3S,5Ss)-5-(diMethylcbaMoyl)pyrrolidin-3-yl]thio]-6-[(1r)-1-hydroxyethyl]-4-Methyl-7-oxo-1-azabicyclo[3.2.0]ht-2-ene-2-cboxylic acid; MEROPENAM; MERREM; MERONEM; Meropenem 10.26; (4R-(3(S*,5S*),4-a,5b,6b(R*)))-3-((5-((Dimethylamino)carbonyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; MeropeneM API; MEROPENEM; (4R,5S,6S)-3-{[(3S,5S)-5-(Dimethylcarbamoyl)-3-pyrrolidinyl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid; Meropenem hydrate; MEROPENEM,USP; MERREM I.V. (meropenem); 1-Azabicyclo[3.2.0]ht-2-ene-2-cboxylic acid, 3-[[5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, [4R-[3(3S*,5S*),4a,5b,6b(R*)]]; Meropenem Crude/ Meropenem Mixture sterile/ sterile; (4r,5s,6s)-3-[[(3s,5s)-5-dimethylcbamoylpyrrolidin-3

物化性质

• 密度: 1.4±0.1 g/cm3
• 沸点: 627.4±55.0 °C at 760 mmHg
• 分子式: C₁₇H₂₅N₃O₅S
• 分子量: 383.462
• 闪点: 333.2±31.5 °C
• 精确质量: 383.151489
• PSA: 135.48000
• LogP: -3.13
• 外观性状: 浅黄色至灰棕色粉末或晶体
• 蒸汽压: 0.0±4.2 mmHg at 25°C
• 折射率: 1.639
• 储存条件: -20°C， 密封， 干燥

生物活性

• 描述: Meropenem是碳青霉烯类广谱抗菌素。
• 相关类别:
  信号通路 >> 抗感染 >> 细菌
  天然产物 >> 生物碱
  研究领域 >> 感染
• 参考文献:

  [1]. Slaney, L., et al., In-vitro activity of meropenem against Neisseria gonorrhoeae, Haemophilus influenzae and H. ducreyi from Canada and Kenya. J Antimicrob Chemother, 1989. 24 Suppl A: p. 183-6.

  [2]. Yang, Y.J. and D.M. Livermore, Interactions of meropenem with class I chromosomal beta-lactamases. J Antimicrob Chemother, 1989. 24 Suppl A: p. 207-17.

  [3]. Makino, J., et al., [Pharmacokinetic study of penetration of meropenem into pleural effusion in patients with pleurisy]. Jpn J Antibiot, 2002. 55(1): p. 77-88.

MSDS

Material Safety Data Sheet Section1. Identification of the substance Product Name: Meropenem Synonyms: Section2. Hazards identification Harmful by inhalation, in contact with skin, and if swallowed. Section3. Composition/information on ingredients. Ingredient name:Meropenem CAS number:96036-03-2 Section4. First aid measures Skin contact:Immediately wash skin with copious amounts of water for at least 15 minutes while removing contaminated clothing and shoes. If irritation persists, seek medical attention. Eye contact:Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical attention. Inhalation:Remove to fresh air. In severe cases or if symptoms persist, seek medical attention. Ingestion:Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention. Section5. Fire fighting measures In the event of a fire involving this material, alone or in combination with other materials, use dry powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus should be worn. Section6. Accidental release measures Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national standards. Respiratory precaution:Wear approved mask/respirator Hand precaution:Wear suitable gloves/gauntlets Skin protection:Wear suitable protective clothing Eye protection:Wear suitable eye protection Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container for disposal. See section 12. Environmental precautions: Do not allow material to enter drains or water courses. Section7. Handling and storage Handling:This product should be handled only by, or under the close supervision of, those properly qualified in the handling and use of potentially hazardous chemicals, who should take into account the fire, health and chemical hazard data given on this sheet. Store in closed vessels, refrigerated. Storage: Section8. Exposure Controls / Personal protection Engineering Controls: Use only in a chemical fume hood. Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles. General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse. Section9. Physical and chemical properties Appearance:Not specified Boiling point:No data No data Melting point: Flash point:No data Density:No data Molecular formula:C17H25N3O5S Molecular weight:383.5 Section10. Stability and reactivity Conditions to avoid: Heat, flames and sparks. Materials to avoid: Oxidizing agents. Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides. Section11. Toxicological information No data. Section12. Ecological information No data. Section13. Disposal consideration Arrange disposal as special waste, by licensed disposal company, in consultation with local waste disposal authority, in accordance with national and regional regulations. Section14. Transportation information Non-harzardous for air and ground transportation. Section15. Regulatory information No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302, or have known CAS numbers that exceed the threshold reporting levels established by SARA Title III, Section 313. SECTION 16 - ADDITIONAL INFORMATION N/A

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : CL5446509 CHEMICAL NAME : 1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-((dimethylamino)carbonyl)- 3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-ox o-, (4R-(3(S*,5S*),4-alpha,5- beta,6-beta(R*)))- CAS REGISTRY NUMBER : 96036-03-2 LAST UPDATED : 199612 DATA ITEMS CITED : 10 MOLECULAR FORMULA : C17-H25-N3-O5-S MOLECULAR WEIGHT : 383.51 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >5 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 40(Suppl 1),182,1992 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >5 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 40(Suppl 1),182,1992 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 2850 mg/kg TOXIC EFFECTS : Peripheral Nerve and Sensation - spastic paralysis with or without sensory change Behavioral - changes in motor activity (specific assay) Lungs, Thorax, or Respiration - dyspnea REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 40(Suppl 1),182,1992 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : >5 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 40(Suppl 1),182,1992 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : >5 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 40(Suppl 1),182,1992 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 2650 mg/kg TOXIC EFFECTS : Behavioral - convulsions or effect on seizure threshold Behavioral - changes in motor activity (specific assay) Behavioral - ataxia REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 40(Suppl 1),182,1992 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Parenteral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : >12 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : JANTAJ Journal of Antibiotics. (Japan Antibiotics Research Assoc., 2-20-8 Kamiosaki, Shinagawa-ku, Tokyo, 141, Japan) V.2-5, 1948-52; V.21- 1968- Volume(issue)/page/year: 45,1983,1992 TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 2 gm/kg TOXIC EFFECTS : Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - acute pulmonary edema Nutritional and Gross Metabolic - body temperature decrease REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 40(Suppl 1),182,1992 ** OTHER MULTIPLE DOSE TOXICITY DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 10920 mg/kg/13W-C TOXIC EFFECTS : Kidney, Ureter, Bladder - other changes in urine composition Endocrine - changes in spleen weight Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - other transferases REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 40(Suppl 1),192,1992 ** REPRODUCTIVE DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 9 gm/kg SEX/DURATION : female 6-17 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) REFERENCE : NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 40(Suppl 1),238,1992

安全

• 危害码 (欧洲): Xi: Irritant;
• 风险声明 (欧洲): R36/37/38
• 安全声明 (欧洲): 26-37/39
• 海关编码: 2933990090

合成路线

上下游产品

上游产品  7
96036-02-1 96034-64-9 141818-52-2 90822-24-5
104873-15-6 96034-57-0 51-35-4
下游产品  0

海关

海关编码	2933990090
中文概述	2933990090. 其他仅含氮杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%
申报要素	品名, 成分含量, 用途, 乌洛托品请注明外观, 6－己内酰胺请注明外观, 签约日期
Summary	2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%